跳转至内容
Merck
CN

N3539

Sigma-Aldrich

尼可地尔

≥98% (HPLC)

别名:

2-(吡啶-3-羰基氨基)乙基硝酸酯, 2-烟酰胺基硝酸乙酯, N-[2-硝氧乙基]-3-吡啶键酰胺, SG-75, 尼可地尔, 烟浪丁

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H9N3O4
CAS号:
分子量:
211.17
EC 号:
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to off-white

溶解性

DMSO: >10 mg/mL

储存温度

room temp

SMILES字符串

[O-][N+](=O)OCCNC(=O)c1cccnc1

InChI

1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)

InChI key

LBHIOVVIQHSOQN-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

尼古拉地尔已被用作钾(K +)通道激活剂和电压门控钙通道抑制剂,用于研究其对人类长QT综合征2(LQTS2)诱导的多能干细胞(hiPSCs)衍生的心肌细胞动作电位(action potential)的影响。

生化/生理作用

尼可地尔是一种杂合ATP敏感性K+(KATP)通道开放剂,也是烟酰胺硝酸盐NO供体。尼可地尔能够选择性激活含有SUR2B-和SUR2A-的KATP通道。它可以增强内皮NO合酶的表达,并防止缺血性室性心律失常。尼可地尔通过激活钾离子通道并提供一氧化氮激活鸟苷酸环化酶,引起GMP活化,从而导致动脉和静脉血管舒张。尼可地尔对血管钾离子通道具有选择性,但对心肌收缩和传导没有明显作用。
尼可地尔(Nicorandil )具有心脏保护作用。

特点和优势

该化合物在受体分类和信号转导手册的钾通道页面上有重点介绍。想要浏览手册的其他页面, 请单击此处

象形图

FlameExclamation mark

警示用语:

Danger

危险声明

危险分类

Acute Tox. 4 Oral - Org. Perox. D

储存分类代码

5.2 - Organic peroxides and self-reacting hazardous materials

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Nicorandil: a drug for many purposes: too good to be true?
Eeckhout E
European heart journal (2003)
A H Gomma et al.
Drugs, 61(12), 1705-1710 (2001-11-06)
Potassium channel openers or agonists represent a novel new class of compounds in the treatment of a range of cardiovascular disorders, particularly angina pectoris and hypertension. Nicorandil is the only clinically available potassium channel opener with antianginal effects, and with
Dene Simpson et al.
Drugs, 64(17), 1941-1955 (2004-08-27)
Nicorandil (Adancor, Angicor, Dancor, Nikoril [Europe], Ikorel [Europe and Oceania], Sigmart [Japan, Korea and Taiwan]) is an adenosine triphosphate (ATP)-sensitive potassium (KATP) channel agonist with nitrate-like properties used in the management of stable angina pectoris. With well established monotherapeutic antianginal
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure.
Amala A Louis et al.
European journal of heart failure, 4(1), 111-116 (2002-01-29)
Kazuhiko Yamamoto et al.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 112(6), 754-759 (2011-08-30)
Nicorandil-induced oral ulceration in 3 Japanese patients is reported. The patients were men aged 86, 81, and 91 years. Ulcers of 15, 10, and 12 mm in diameter, respectively, were observed at the border of all of the patients' tongues.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门